Menu
Search Close

Investors

Share Information

Other exchanges or trading platforms where Scancell Holdings plc securities are admitted or traded:

Scancell Holdings securities are listed on AIM, and the latest share price is shown here

The number of securities in issue:

The company has an issued share capital of 387,796,556 ordinary shares of 0.1p each, all of which are called up and fully paid.

Pursuant to the License and Supply Agreement (‘the Agreement’) dated 13 July 2009, the Company has granted options over 3,184,630 ordinary shares to ICHOR at 4.5p per share.

Directors’ Share Options:

The Company has granted the following options to Directors of the Company. 

Option holder

Option price per ordinary share

Number of ordinary shares under option

Last day of exercise period

Sally Adams

10.5p

2,500,000

30 January 2028

John Chiplin

17.0p

3,000,000

18 April 2026

 Lindy Durrant

4.5p

3,850,000

14 July 2020

Lindy Durrant

10.5p

9,000,000

30 January 2028

Richard  Goodfellow

4.5p

2,880,000

14 July 2020

Richard  Goodfellow

33.2p

3,500,000

31 December 2023

Clifford Holloway

10.5p

3,000,000

30 January 2028

 

In addition to the above, the Company has granted options over 4,645,536 shares of the Company to various other persons at exercise prices between 2.5p and 33.2p.

Percentage of AIM securities not in public hands:

As at 25 July 2018 the percentage of AIM securities not in public hands was: 17.86%

Restrictions on the transfer of securities:

There are no restrictions on the transfer of shares.

Identity and percentage holdings of significant shareholders:

As at 25 July 2018 the identity and percentage holdings of significant shareholders were: 

 

Ordinary shares at 0.1p each

 

 Number

 Percentage

Calculus Capital

49,983,268

12.89%

City Financial Investment Company

21,787,775

5.62%

Scancell Holdings plc directors and related holdings

19,277,898

4.97%

Legal & General Investment Management

18,167,000

4.68%

Hygea VCT plc

13,249,730

3.42%

Scientific Papers

Novel tumour antigens and the development of optimal vaccine design (2018)

Victoria A Brentville, Suha Atabani, Katherine Cook and Lindy G Durrant


Current Strategies to Enhance Anti-Tumour Immunity (2018)

Katherine W Cook, Lindy G Durrant and Victoria A Brentville


Autophagy, citrullination and cancer (2016)

Lindy G. Durrant, Rachael L. Metheringham and Victoria A. Brentville


SCIB1 combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors (2016)

Wei Xue, Victoria A. Brentville, Peter Symonds, Katherine W. Cook, Hideo Yagita, Rachael L. Metheringham and Lindy G. Durrant


SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes (2016)

Wei Xue, Rachael L. Metheringham, Victoria A. Brentville, Barbara Gunn, Peter Symonds, Hideo Yagita, Judith M.  Ramage and Lindy G. Durrant


Citrullinated Vimentin presented on MHC-II in Tumor Cells is a target for CD4þ T-cell-mediated antitumor immunity (2016)

Victoria A. Brentville, Rachael L. Metheringham, Barbara Gunn, Peter Symonds, Ian Daniels, Mohamed Gijon, Katherine Cook, Wei Xue and Lindy G. Durrant 


High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment (2012) 
Victoria A. Brentville, Rachael L. Metheringham, Barbara Gunn and Lindy G. Durrant


Using monoclonal antibodies to stimulate antitumour cellular immunity (2011)
Lindy Durrant, Victoria Pudney and Ian Spendlove


Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses (2010)
Lindy Durrant, Victoria Pudney, Ian Spendlove and Rachael Metheringham


DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8 T cells (2009)
Victoria A. Pudney, Rachael L. Metheringham, Barbara Gunn, Ian Spendlove, Judith M. Ramage and Lindy G. Durrant


Antibodies designed as effective cancer vaccines (2009)
R.L. Metheringham, V.A. Pudney, B. Gunn, M. Towey, I. Spendlove and L.G. Durrant



Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4 T-Cell–Mediated Antitumor Immunity

Victoria A. Brentville, Rachael L. Metheringham, Barbara Gunn, Peter Symonds, Ian Daniels, Mohamed Gijon, Katherine Cook, Wei Xue, and Lindy G. Durrant


ASCO Poster June 2015

P.M Patel, C Ottensmeier, C Mulatero, P Lorigan, R Plummer, M Cunnell, R Metheringham, V Brentville, L Machado, I Daniels, D Hannaman, L.G Durrant


AACR Moditope® poster April 2015 

Victoria A Brentville, Rachael L Metheringham, Barbara Gunn, Peter Symonds, Ian Daniels, Mohamed Gijon, Wei Xue, Lindy G Durrant


High Avidity Cytotoxic T Lymphocytes Can Be Selected into the Memory Pool but They Are Exquisitely Sensitive to Functional Impairment
Victoria A. Brentville, Rachael L. Metheringham, Barbara Gun and Lindy G. Durrant


Using monoclonal antibodies to stimulate antitumour cellular immunity
Lindy Durrant, Victoria Pudney and Ian Spendlove

ASCO poster June 2014
P.M Patel, L.G Durrant, C. Ottensmeier, C. Mulatero, P. Lorigan, R. Plummer, M. Cunnell, R. Metheringham, V. Brentville, L. Machado, I. Daniels and D. Hannaman


Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses
Lindy Durrant, Victoria Pudney, Ian Spendlove and Rachel Metheringham


DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8 T cells
Victoria A. Pudney, Rachael L. Metheringham, Barbara Gunn, Ian Spendlove, Judith M. Ramage and Lindy G. Durrant


Antibodies designed as effective cancer vaccines
R.L. Metheringham, V.A. Pudney, B. Gunn, M. Towey, I. Spendlove and L.G. Durrant


Webcasts, Interviews and Media Coverage

Scancell’s Modi-2 anti-cancer vaccine shows potential in pre-clinical studies

Modi-2 is the second vaccine developed from the Moditope platform after Modi-1, and Scancell thinks each one has the potential to treat different types of cancer

Tue, 30 Oct 2018 14:05:00

Scancell says it is working closely with US regulators ahead of phase II study of cancer immunotherapy

The UK group is planning to use its SCIB1 in harness with Merck’s Keytruda to treat patients with advanced melanoma

Wed, 24 Oct 2018 05:40:00

Scancell Holdings part of the new cancer revolution

The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology

Tue, 25 Sep 2018 06:20:00